Advances in imaging for systemic sclerosis.

pa-Review Systemic sclerosis: one year in review 2026

Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives

This narrative review summarizes current evidence on established and emerging serum and molecular biomarkers in SSc-ILD and their potential clinical applications and highlights the potential of circulating and molecular biomarkers to refine risk stratification and prognostic assessment in SSc-ILD.

Biologics in Systemic Sclerosis: An Organ- and Manifestation-Specific Reappraisal of What Has Changed, What Has Not, and Why

This focused narrative review reappraises biologic therapies in SSc using a manifestation-based framework spanning cutaneous, pulmonary, vascular, gastrointestinal, musculoskeletal, and global or composite outcomes and argues that vasculopathy may represent an upstream pathogenic layer that constrains the disease-modif...

Juvenile-onset systemic lupus erythematosus in the treat-to-target era: recent advances in outcome assessment

Juvenile-onset systemic lupus erythematosus (jSLE) is a rare, severe multisystem autoimmune/inflammatory disease associated with early morbidity, cumulative treatment toxicity, and long-term organ damage. In this context, outcome assessment is central to both clinical care and research, yet remains particularly chall...

Updates on the Evaluation of Lupus Arthritis

Lupus arthritis is the most common manifestation of systemic lupus erythematosus (SLE), affecting up to 95% of patients. Clinical presentations range from inflammatory arthralgia and non-deforming non-erosive (NDNE) synovitis to Jaccoud arthropathy and erosive arthritis, reflecting substantial clinical heterogeneity. D...

Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies.

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system for which more than 20 disease-modifying therapies (DMTs) are currently available. Recent advances in diagnostic criteria, biomarker development, and understanding of disease biology have challenged traditiona...